Know Cancer

forgot password

Consortium for the Sharing of Germ Line DNA and Tissue From Subjects With Mesothelioma

18 Years
Open (Enrolling)

Thank you

Trial Information

Consortium for the Sharing of Germ Line DNA and Tissue From Subjects With Mesothelioma

Mesothelioma is a cancer that develops from serosal surfaces usually in response to prior
asbestos exposure. A history of asbestos exposure can be elicited in more than 80% of
mesothelioma victims. However, asbestos exposure alone is not sufficient to cause the
development of mesothelioma. Nearly 27 million individuals in the US, were exposed to
asbestos in the work place between 1940 and 1979 but just 3,000 new cases of mesothelioma
are diagnosed each year. Therefore, the investigators hypothesis is that genetic variation
in addition to asbestos exposure, and host factors contribute to the development of
mesothelioma. It is estimated, based on the investigators preliminary studies, that a
population in excess of 1,000 subjects with mesothelioma is required to perform a valid

Therefore a multicenter approach is necessary to collect data and DNA on sufficient numbers
with mesothelioma to adequately evaluate genetic risk. It is the aim of this proposal to
develop a consortium of mesothelioma investigators to share phenotypic data and DNA samples
and to perform genome wide association scanning (GWAS).

Inclusion Criteria:

- Subjects able to provide informed consent who suffer from mesothelioma

Exclusion Criteria:

- Inability to provide informed consent

- Absence of mesothelioma in self

Type of Study:


Study Design:

Observational Model: Case-Only, Time Perspective: Cross-Sectional

Outcome Measure:

Creation of a consortium of investigators (7 sites) for collection of blood for germline DNA and demographic information from 1000 mesothelioma subjects.

Outcome Description:

Demographic variables that will be collected include; date of birth, gender, age at first exposure to asbestos, type of exposure (occupational or bystander), family health history, personal past medical history, smoking history, age at diagnosis, latency, tumor location and cell type.

Outcome Time Frame:

Participants will be seen on one occasion lasting 30-60 min to draw blood and elicit demographic information. It will require up to 2 years to enroll 1000 subjects with mesothelioma from the various sites.

Safety Issue:


Principal Investigator

Jill Ohar, MD

Investigator Role:

Study Director

Investigator Affiliation:

Wake Forest University


United States: Institutional Review Board

Study ID:

GTS 36076 MARF



Start Date:

June 2011

Completion Date:

December 2014

Related Keywords:

  • Mesothelioma
  • Genetics of Mesothelioma
  • Mesothelioma Consortium
  • GWAS
  • Asbestos
  • Mesothelioma



Johns Hopkins University Baltimore, Maryland  21205
Memorial Sloan Kettering Cancer Center New York, New York  10021
Mayo Clinic Rochester, Minnesota  55905
Mount Sinai School of Medicine New York, New York  10029
University of Pennsylvania Philadelphia, Pennsylvania  19104
New York University School of Medicine New York, New York  10016
Wake Forest University Health Sciences Winston-Salem, North Carolina  27157